Lineage Cell Therapeutics
LCTX
102 hedge funds and large institutions have $140M invested in Lineage Cell Therapeutics in 2017 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 42 increasing their positions, 19 reducing their positions, and 12 closing their positions.
121% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 19
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
0.87% less ownership
Funds ownership: 49.51% → 48.64% (-0.87%)
4% less call options, than puts
Call options by funds: $203K | Put options by funds: $212K
6% less funds holding
Funds holding: 109 → 102 (-7)
7% less capital invested
Capital invested by funds: $151M → $140M (-$11.3M)
50% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
+$1.53M |
| 2 |
Renaissance Technologies
New York
|
+$750K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$678K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$629K |
| 5 |
BC
Broadwood Capital
New York
|
+$453K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MHP
Manatuck Hill Partners
Westport,
Connecticut
|
-$761K |
| 2 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
-$227K |
| 3 |
Charles Schwab
San Francisco,
California
|
-$164K |
| 4 |
Russell Investments Group
London,
United Kingdom
|
-$156K |
| 5 |
Millennium Management
New York
|
-$153K |
LCTX Hedge Fund Activity: Q3 2017 in Review
102 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q3 2017, worth a combined $140M — down 7.5% from $151M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of LCTX and 6 opened new positions — a net loss of 6 holders — while 19 trimmed existing stakes and 42 added.
The largest buyer was Northern Trust, adding an estimated $1.53M. The largest seller was Manatuck Hill Partners, cutting an estimated $761K.
- 102 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q3 2017, down from 109 in Q2 2017.
- Funds reported $140M of Lineage Cell Therapeutics stock for Q3 2017, down 7.5% quarter-over-quarter.
- 6 funds opened new Lineage Cell Therapeutics positions in Q3 2017 and 12 closed out, a net change of -6 holders.
- The largest Lineage Cell Therapeutics buyer in Q3 2017 was Northern Trust, an estimated $1.53M added.
- The largest Lineage Cell Therapeutics seller in Q3 2017 was Manatuck Hill Partners, an estimated $761K sold.
Based on aggregated 13F filings for Q3 2017.